Search

everythinglearnresearchcommunity

for

Search:↓

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.

The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

The product being promoted is likely ineffective for hair regrowth, as it lacks key ingredients like minoxidil and finasteride, and may rely on deceptive marketing tactics such as lighting tricks. Users suggest that proven treatments like minoxidil and finasteride are more reliable for hair loss.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.

The user shared their hair loss journey, using 0.5mg finasteride, topical minoxidil, and dermarolling initially, then increasing to 1mg finasteride and adding 2.5mg oral minoxidil. They experienced significant regrowth but are currently facing a prolonged shedding phase, hoping for stabilization and regrowth.

A 21-year-old male shared his extensive hair loss treatment protocol, which includes Dutasteride, RU58841, Ketoconazole shampoo, oral Minoxidil, pyrilutamide, MK677, dermastamping, and castor oil, and reported improved hair regrowth and overall well-being. He has experienced no side effects and has also improved his diet and lifestyle.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

A user initially had side effects from finasteride, attributed them to anxiety and the nocebo effect, and after resuming the drug, experienced positive effects and now warns against misinformation about Post Finasteride Syndrome.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.

User is experiencing hair shedding after 7 months of using finasteride 1mg daily and asks if they should continue. Their routine includes finasteride, topical minoxidil, dermarolling, and vitamins like biotin and B12.

RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.

The conversation discusses a hair loss regimen involving finasteride, dutasteride, minoxidil, RU58841, and various supplements like biotin, omega-3, vitamin D3, zinc, and magnesium. The user also uses dermastamping and topicals like ketoconazole and diclofenac, with mixed opinions on zinc's effect on hair loss.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

Hair loss treatment effectiveness varies by individual response, with some seeing results from low doses of finasteride while others see no improvement from more aggressive treatments. The consensus is that finasteride, dutasteride, and minoxidil are effective, but their success depends on personal biology.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Red light therapy with dual wavelengths (650nm and 850nm) can stimulate hair regrowth without DHT blockers. Consistent use of a panel with these wavelengths has shown positive results in hair regrowth.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.